Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Rxo (RXO) EBIT Margin (2021 - 2025)

Historic EBIT Margin for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to 2.86%.

  • Rxo's EBIT Margin fell 14200.0% to 2.86% in Q4 2025 from the same period last year, while for Dec 2025 it was 1.38%, marking a year-over-year decrease of 1500.0%. This contributed to the annual value of 1.38% for FY2025, which is 1500.0% down from last year.
  • Latest data reveals that Rxo reported EBIT Margin of 2.86% as of Q4 2025, which was down 14200.0% from 0.49% recorded in Q3 2025.
  • In the past 5 years, Rxo's EBIT Margin registered a high of 4.73% during Q2 2022, and its lowest value of 2.86% during Q4 2025.
  • For the 5-year period, Rxo's EBIT Margin averaged around 0.69%, with its median value being 0.55% (2023).
  • Its EBIT Margin has fluctuated over the past 5 years, first tumbled by -42300bps in 2022, then surged by 15200bps in 2023.
  • Quarter analysis of 5 years shows Rxo's EBIT Margin stood at 4.14% in 2021, then plummeted by -102bps to 0.09% in 2022, then skyrocketed by 1703bps to 1.43% in 2023, then crashed by -201bps to 1.44% in 2024, then tumbled by -99bps to 2.86% in 2025.
  • Its EBIT Margin stands at 2.86% for Q4 2025, versus 0.49% for Q3 2025 and 2.09% for Q1 2025.